Prediction of Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on Ga-DOTATATE PET/CT.

Background: Treatment of metastatic neuroendocrine tumors (NET) with Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) results in favorable response only in a subset of patients. We investigated the prognostic value of quantitative pre-treatment semi-automatic Ga-DOTATATE PET/CT analysis in NET patients treated with PRRT.

Methods: The medical records of 94 NET patients who received at least one cycle of PRRT at a single institution were retrospectively reviewed.

Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing Lu-PSMA-I&T Therapy.

Lu-PSMA is an effective treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and adjust treatment may be improved using predictive tools. This study aimed to evaluate change in Lu-PSMA SPECT quantitative parameters to monitor treatment response.

Evaluation of Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).

Lu-PSMA-617 is an effective and novel treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and therefore efficacy may be improved using predictive tools. This study investigated the predictive value of serial Lu-PSMA-617 SPECT/CT (Lu SPECT) imaging in monitoring treatment response.

The Prognostic Value of Posttreatment Ga-PSMA-11 PET/CT and F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).

Lu-PSMA-617 therapy has shown high prostate-specific antigen (PSA) response rates in men with metastatic castration-resistant prostate cancer. However, early treatment resistance is common. This LuPIN substudy aimed to determine the prognostic value of posttreatment quantitative PET for PSA progression-free survival (PFS) and overall survival (OS) with Lu-PSMA-617 therapy.